首页> 中文期刊> 《国际感染杂志(电子版)》 >The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Patients with Chronic Hepatitis C Receiving a Personalized Treatment Program

The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Patients with Chronic Hepatitis C Receiving a Personalized Treatment Program

         

摘要

Objective To investigate the effects of individualised treatment with peginterferon alpha-2a (40 kD) plus ribavirin in Chinese patients with CHC. Methods Total of 297 consecutive Chinese patients were enrolled, including 250 naïve cases and 47 cases who were previously treated. Treatment duration was determined according to viral genotypes, prior treatment history and viral responses at week 4, 12 and 24. Results Totally, 235 patients (79.1%) completed treatment and 186 (87.3%) achieved SVR. And 219 out of 289 (75.8%) patients achieved HCV RNA negative at week 4 (RVR) and 259 of 276 (93.8%) at week 12. Among the 164 patients with RVR who completed follow-up, 158 (96.3%) achieved SVR. Patients with RVR had lower baseline viral loads than patients without RVR (P=0.034). The positive predictive value (PPV) of RVR for SVR was 90.7%(OR 2.10 vs. non-RVR, 95%CI:0.50-8.7). Similar outcomes were observed among patients with HCV undetectable at week 12. Conclusions Viral suppression by week 4 is associated with a high rate of treatment success in treatment naïve and experienced patients receiving individualized CHC therapy.

著录项

  • 来源
    《国际感染杂志(电子版)》 |2013年第2期|60-70|共11页
  • 作者单位

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Medical Record Library, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Clinical Test Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Clinical Test Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;

    Department of Infectious Diseases, Beijing Haidian Hospital, Beijing 100080, China;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号